Skip to main contentAI and Advanced
/
ERIS · NSEBSE SENSEX74,294.96-0.03%BSE |
NIFTY 5023,346.4+0.33%NSE |
NIFTY BANK56,358.7+0.54%NSE |
NIFTY IT28,854.55-1.03%NSE |
NIFTY AUTO27,129-0.11%NSE |
NIFTY FMCG45,466.8-0.23%NSE |
NIFTY PHARMA26,710.1+0.49%NSE |
NIFTY 50022,840.55+0.82%NSE |
ER
NSE · Equity shares · Biotechnology & Drugs1.90 · 0.14%
Eris Lifesciences ERIS
NSE:INR 1,312.6
BSE:INR 1,310
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for ERIS
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,310.7
Day rangeINR 1,303.1 — INR 1,355.1
52-week rangeINR 1,200 — INR 1,854
Volume1.43 L
Market cap19,248.42
P/E30.49
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)3,129.42
Net Income (INR Cr)619.52
Rev Growth (5 Year %)20.89
EPS Growth (5 Year %)11.61
P/E Ratio30.49
EPS46.08
Research path: Interpret Eris Lifesciences's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ERISEris Lifesciences1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 7,365.51 | 7,033.17 | 7,040.46 |
| Cash Equivalents | 12.56 | Not available | Not available |
| Other Liabilities Total | 91.65 | 79.85 | 60.38 |
| Long Term Debt | 955.83 | 1,737.51 | 654.51 |
| Common Stock Total | 13.85 | 13.62 | 13.6 |
| Other Current Assets Total | 293.56 | 25.5 | 63.87 |
| Total Assets | 7,365.51 | 7,033.17 | 7,040.46 |
| Current Portof LT Debt/Capital Leases | 1,362.6 | 299.61 | 340.93 |
| Cash | 54.74 | 199.64 | 94.14 |
| Total Equity | 3,902.67 | 2,854.36 | 2,586.18 |
| Long Term Investments | 71.39 | 62.2 | 15.73 |
| Retained Earnings(Accumulated Deficit) | 3,888.82 | 2,811.4 | 2,554.51 |
| Total Common Shares Outstanding | 13.85 | 13.62 | 13.6 |
| Tangible Book Valueper Share Common Eq | -41.61 | -131.48 | -87.8 |
| Goodwill Net | 911.97 | 911.97 | 867.17 |
| Total Liabilities | 3,462.84 | 4,178.81 | 4,454.28 |
| Total Debt | 2,358.62 | 2,477.92 | 2,781.27 |
| Short Term Investments | 9.08 | 5.73 | 1,244.61 |
| Cashand Short Term Investments | 76.38 | 205.37 | 1,338.75 |
| Total Receivables Net | 733.09 | 582.48 | 571.18 |
| Deferred Income Tax | 305.08 | 518.45 | 534.39 |
| Accounts Receivable-Trade Net | 680.34 | 458.64 | 422.08 |
| Property/Plant/Equipment Total-Net | 879.84 | 728.81 | 558.31 |
| Minority Interest | -7.01 | 417.4 | 635.91 |
| Total Current Liabilities | 2,077.1 | 1,381.39 | 2,532.07 |
| Total Inventory | 436.82 | 389.6 | 302.62 |
| Accounts Payable | 329.65 | 332.35 | 218.93 |
| Other Currentliabilities Total | 384.85 | 203.61 | 163.75 |
| Total Long Term Debt | 996.02 | 1,781.72 | 691.53 |
| Intangibles Net | 3,567.22 | 3,732.71 | 2,913.35 |
| Other Long Term Assets Total | 353.46 | 301.8 | 318.18 |
| Note Receivable-Long Term | 41.78 | 72.69 | 65.68 |
| Total Current Assets | 1,539.85 | 1,222.99 | 2,302.04 |
| Capital Lease Obligations | 40.19 | 44.21 | 37.02 |
| Accumulated Depreciation Total | Not available | -221.31 | -145.04 |
| Accrued Expenses | Not available | 149.23 | 59.65 |
| Prepaid Expenses | Not available | 20.04 | 25.62 |
| Additional Paid-In Capital | Not available | 29.34 | 18.07 |
| Property/Plant/Equipment Total-Gross | Not available | 883.37 | 684.29 |
| Notes Payable/Short Term Debt | Not available | 396.59 | 1,748.81 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.7
Price to Sale Ratio6.15
Growth
Debt 5Yr CAGR %222.35
Margins
Operating Margin 12m26.05
Operating Margin 5y Avg25.91
Net Profit Margin 12m20.61
Net Profit Margin 5y19.88
Yield
Dividend Yield %0.52
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk31.94
Analyst consensus
ConsensusStrong Buy
Consensus score1.60
Analyst opinions10
Strong Sell count0
Sell count0
Hold count1
Buy count4
Strong Buy count5
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,951 | 4.68 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 54.14%
- FII
- 5.76%
- MF
- 18.88%
- Other
- 21.22%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
ERIS Lifesciences Ltd Valuation Shifts Signal Changing Market Sentiment - Markets MojoMarket news · 4 Jun 2026, 5:25 pm
ERIS Lifesciences Ltd Valuation Shifts Signal Changing Market Sentiment Markets Mojo
Eris Lifesciences - Ipca Laboratories among 5 stocks showing bullish RSI upswing - The Economic TimesMarket news · 4 Jun 2026, 9:16 am
Eris Lifesciences - Ipca Laboratories among 5 stocks showing bullish RSI upswing The Economic Times
ERIS Lifesciences Ltd is Rated Hold - Markets MojoMarket news · 2 Jun 2026, 4:01 pm
ERIS Lifesciences Ltd is Rated Hold Markets Mojo
Eris Lifesciences fined ₹4.24 lakh for board composition lapse - scanx.tradeMarket news · 28 May 2026, 4:30 pm
Eris Lifesciences fined ₹4.24 lakh for board composition lapse scanx.trade
Eris promoters confirm no encumbrance on 53.92% stake - scanx.tradeMarket news · 28 May 2026, 9:00 am
Eris promoters confirm no encumbrance on 53.92% stake scanx.trade
Eris Lifesciences posts analyst call transcript for Q4FY26 - scanx.tradeMarket news · 27 May 2026, 12:30 pm
Eris Lifesciences posts analyst call transcript for Q4FY26 scanx.trade
Corporate actions
Events
- board MeetingsQuarterly Results
- dividendRs.7.2100 per share(721%)Interim Dividend
- annual General MeetingPOM
- board MeetingsAudited Results & Interim Dividend
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsInter-alia, To consider the protposal of issuance ofequity shares of the Company by way of a preferential issue for consideration other than cash..
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Eris Lifesciences
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Eris Lifesciences Limited is an India-based pharmaceutical company. The Company is engaged in the manufacture and marketing of pharmaceutical products. The Company has a presence in major therapies like oral anti-diabetes, insulins, cardiovascular, vitamins/minerals and dermatology. Its flagship therapies include oral anti-diabetes, cardiovascular disease (CVD), and vitamins, minerals and nutrients (VMN). Its emerging therapies consist of dermatology, insulins, women’s health, central nervous system (CNS), oncology, and nephrology. Its portfolio of brands includes Glimisave, Eritel, LNBloc, Olmin, Crevast, Atorsave, Gluxit, Renerve, Zomelis, Cosvate, Tayo, Cyblex, Remylin, Tendia, Rabonik, Ginkocer, Psorid, Raricap, Serlift, and Onabet, among others. Its patient care initiatives (PCI) platform provides various healthcare solutions to its patients. The Company has a manufacturing plant located in Guwahati, Assam.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- ERIS
- BSE Code
- 540596
Questions
Stock FAQ
What is the symbol and ISIN of Eris Lifesciences?
Eris Lifesciences has the symbol ERIS and ISIN - INE406M01024.
What is the current price of Eris Lifesciences?
Eris Lifesciences is currently trading at INR 1,312.60.
What are the year high and year low of Eris Lifesciences?
Eris Lifesciences has a year high of INR 1,854.00 and a year low of INR 1,200.00.
What is the market capitalization of Eris Lifesciences?
Eris Lifesciences has a market capitalization of INR 19,248.42 crore.
What is the P/E ratio of Eris Lifesciences?
Eris Lifesciences has a P/E ratio of 30.49.
What is the dividend yield of Eris Lifesciences?
Eris Lifesciences has a dividend yield of 0.52%.
How is the financial performance of Eris Lifesciences based on revenue, net income, and EPS?
Eris Lifesciences has revenue of INR 3,129.42 crore, net income of INR 619.52 crore, and EPS of INR 47.90.
What is the book value of Eris Lifesciences?
Eris Lifesciences has a book value of NA.
What is the debt-to-equity ratio of Eris Lifesciences?
Eris Lifesciences has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Eris Lifesciences?
Eris Lifesciences has a price-to-book ratio of NA and a price-to-sales ratio of 6.15.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.